Sundar Jagannath, Md, Discusses Promising Data From Asco Regarding Multiple Myeloma

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

Dr. Sundar Jagannath Discusses the Approval of Lenalidomide in Multiple Myeloma

Dr. Sundar Jagannath on Three-Drug Regimen for Newly Diagnosed Multiple Myeloma

Dr. Jagannath on Immunotherapy in Multiple Myeloma

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

Managing the challenges associated with continuous BCMA-directed therapy in multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

Dr. Jagannath Discusses Advances in the Management of Relapsed Multiple Myeloma

Targeted Oncology

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM

Dr.Jagannath on Role for Two-Drug Combinations, Carfilzomib Triplet in Multiple Myeloma

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

Dr. Jagannath on Pomalidomide in Relapsed or Refractory Multiple Myeloma

Targeted Oncology

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma